Different course of reactive arthritis in two HLA-B27 positive brotherswith fatal outcome in one
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns="http://www.w3.org/TR/REC-html40">
Different course of reactive arthritis in two HLA-B27 positive brothers
with fatal outcome in one
Different course of reactive arthritis in two
HLA-B27 positive brothers with fatal outcome in one.
Yli-Kerttula T, Mottonen T, Toivanen A.
Department of Medicine, Turku University, Finland.
During an outbreak of Yersinia pseudotuberculosis III, one of two HLA-B27
positive brothers developed reactive arthritis (ReA), mild at first, but later
severely destructive and ultimately fatal. The reactivation of ReA was possibly
triggered by an oral polio vaccine. The cause of death was severe secondary
amyloidosis. The other brother was exposed to the same Y. pseudotuberculosis
strain but did not develop any disease during or after the outbreak. However,
he later developed ReA due to a Salmonella infection, with a benign course.
PMID: 9330954 [PubMed - indexed for MEDLINE]
ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.
"A foolish faith in authority is the worst enemy of truth."
-- Albert Einstein, letter to a friend, 1901
"I know of no safe depository of the ultimate powers of the society but the people themselves, and if we think them not enlightened enough to exercise control with a wholesome discretion, the remedy is not to take it from them, but to inform their discretion by education."
-- Thomas Jefferson, letter to William C. Jarvis, September 28, 1820
Sandy's Scandals Column
Past and current Scandals
- columns by Sandy Gottstein (aka Mintz)*
* ►March 20, 2010
- Taking
the Final Step: Implementation of a Mandatory Flu Shot Program Within a
Healthcare System - Fifth Decennial International Conference
on Healthcare-Associated Infections (abstract) - "Exemption from
vaccination was allowed for egg allergy, history of either
Guillian-Barré or a post-flu shot anaphylaxis. A formal
exemption process began as a written appeal to an internal review board
which determined exemption. For the non-exempt, the choice to not be
vaccinated resulted in termination. Rehire is conditional, based on the
intent to comply with influenza vaccination in the future. ...Over
99.99% of approximately 3800 employees received a seasonal flu shot. No
serious side effects occurred among those receiving vaccine. Of those
employees who applied for exemption but were denied, 4 chose to
terminate employement; however, one of these, a physician, chose
retirement rather than immunization. Consequences for unvaccinated,
non-employees were not explored this initial year."
* ►March 19, 2010
- Autism,
Vaccines, Thimerosal: Further Study Needed - Age of Autism -
"No study has looked at the possible effect of the synergistic toxicity
of aluminum and thimerosal, which are never supposed to be used in
combination (according to the Manufacturer Safety Data Sheet (MSDS)
for thimerosal ) and are indeed combined in many shots (according to
the Vaccine Excipient Summary from the
CDC). And no controlled study, not one, exists on the effect of
low dose ethyl mercury toxicity in humans (a statement made by study
author Anders Hviid himself below on p.1765)."
* ►March 18, 2010
- FDA
to Ease Way for Multidrug Regimens (MRK,AZN) - SmarTrend News Watch
via COMTEX via Trading Markets - "At least two pharmaceutical consortia
are poised to take advantage of the forthcoming policy: a group of 10
drug companies and several nonprofit organizations convened by the Bill
and Melinda Gates Foundation to develop medicines to fight
tuberculosis; and pharmaceutical giants Merck & Co. (NYSE: MRK |
Quote | Chart | News | PowerRating) and AstraZeneca PLC (NYSE: AZN |
Quote | Chart | News | PowerRating), which are jointly testing two
anticancer agents."